<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>PSA Testing Quick Reference | Clinical Tool</title>
    <style>
        :root {
            /* Palette */
            --color-bg: #f4f7f9;
            --color-surface: #ffffff;
            --color-text-primary: #1d2d3f;
            --color-text-secondary: #546e7a;
            
            /* Clinical Codes */
            --color-urgent: #e63946; /* Red - Flags/Symptomatic */
            --color-safe: #2a9d8f;   /* Green - Safe/Choice */
            --color-info: #457b9d;   /* Blue - Neutral/Info */
            --color-warning: #e9c46a; /* Amber - Caution */
            
            /* Spacing & Borders */
            --radius-md: 8px;
            --radius-lg: 12px;
            --shadow-sm: 0 1px 3px rgba(0,0,0,0.1);
            --shadow-md: 0 4px 6px rgba(0,0,0,0.08);
            --shadow-hover: 0 10px 15px rgba(0,0,0,0.1);
        }

        * {
            box-sizing: border-box;
            margin: 0;
            padding: 0;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Helvetica, Arial, sans-serif;
            background-color: var(--color-bg);
            color: var(--color-text-primary);
            line-height: 1.5;
            padding-bottom: 40px;
        }

        /* --- Typography --- */
        h1, h2, h3, h4 {
            font-weight: 700;
            letter-spacing: -0.02em;
        }
        
        h1 { font-size: 1.5rem; }
        h2 { font-size: 1.25rem; margin-bottom: 1rem; display: flex; align-items: center; gap: 0.5rem; }
        h3 { font-size: 1.1rem; margin-bottom: 0.75rem; color: var(--color-text-primary); }
        p { margin-bottom: 0.75rem; font-size: 0.95rem; color: var(--color-text-secondary); }
        ul { list-style: none; }
        
        /* --- Layout Components --- */
        .container {
            max-width: 1000px;
            margin: 0 auto;
            padding: 0 16px;
        }

        .header {
            background: var(--color-surface);
            border-bottom: 4px solid var(--color-info);
            padding: 1.5rem 0;
            margin-bottom: 2rem;
            box-shadow: var(--shadow-sm);
        }
        
        .header-content {
            display: flex;
            justify-content: space-between;
            align-items: center;
        }

        .badge {
            font-size: 0.75rem;
            text-transform: uppercase;
            padding: 4px 8px;
            border-radius: 4px;
            font-weight: 700;
            letter-spacing: 0.05em;
        }
        .badge-red { background: #ffebee; color: var(--color-urgent); }
        .badge-green { background: #e0f2f1; color: var(--color-safe); }
        .badge-blue { background: #e1f5fe; color: var(--color-info); }

        /* --- The Triage Section (Hero) --- */
        .triage-grid {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 1.5rem;
            margin-bottom: 2.5rem;
        }

        @media (max-width: 768px) {
            .triage-grid { grid-template-columns: 1fr; }
        }

        .triage-card {
            background: var(--color-surface);
            border-radius: var(--radius-lg);
            padding: 1.5rem;
            box-shadow: var(--shadow-md);
            transition: transform 0.2s ease, box-shadow 0.2s ease;
            border-top: 6px solid transparent;
            cursor: pointer;
            position: relative;
            overflow: hidden;
        }

        .triage-card:hover {
            transform: translateY(-4px);
            box-shadow: var(--shadow-hover);
        }

        .triage-urgent {
            border-color: var(--color-urgent);
        }
        .triage-urgent:hover { background-color: #fff5f5; }

        .triage-routine {
            border-color: var(--color-safe);
        }
        .triage-routine:hover { background-color: #f0fdf4; }

        .icon-large {
            font-size: 2rem;
            margin-bottom: 0.5rem;
            display: block;
        }

        /* --- Quick Reference Bar (Thresholds) --- */
        .threshold-bar {
            background: #263238;
            color: white;
            padding: 1rem;
            border-radius: var(--radius-lg);
            margin-bottom: 2rem;
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            justify-content: space-between;
            gap: 1rem;
        }

        .threshold-table {
            width: 100%;
            border-collapse: collapse;
            font-size: 0.9rem;
        }
        
        .threshold-table th { text-align: left; opacity: 0.7; padding-right: 1rem; }
        .threshold-table td { font-weight: 700; color: var(--color-warning); }

        /* --- Risk Factors Grid --- */
        .risk-section {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 1.5rem;
            margin-bottom: 2.5rem;
        }

        .card {
            background: var(--color-surface);
            padding: 1.25rem;
            border-radius: var(--radius-md);
            border: 1px solid #e0e0e0;
            box-shadow: var(--shadow-sm);
        }

        .card.highlight {
            border-left: 4px solid var(--color-info);
        }

        .risk-stat {
            font-size: 1.5rem;
            font-weight: 800;
            color: var(--color-urgent);
            margin: 0.5rem 0;
        }

        /* --- Tabs System --- */
        .tabs {
            display: flex;
            gap: 0.5rem;
            margin-bottom: 1rem;
            overflow-x: auto;
            padding-bottom: 4px;
        }

        .tab-btn {
            background: #e0e0e0;
            border: none;
            padding: 0.75rem 1.25rem;
            border-radius: 20px;
            font-weight: 600;
            cursor: pointer;
            color: var(--color-text-secondary);
            transition: all 0.2s;
            white-space: nowrap;
        }

        .tab-btn.active {
            background: var(--color-info);
            color: white;
            box-shadow: var(--shadow-sm);
        }

        .tab-content {
            display: none;
            animation: fadeIn 0.3s ease;
        }
        .tab-content.active { display: block; }

        @keyframes fadeIn {
            from { opacity: 0; transform: translateY(5px); }
            to { opacity: 1; transform: translateY(0); }
        }

        /* --- Utility Tables --- */
        .data-table {
            width: 100%;
            border-collapse: collapse;
            margin-top: 0.5rem;
        }
        .data-table th, .data-table td {
            padding: 0.75rem;
            text-align: left;
            border-bottom: 1px solid #eee;
        }
        .data-table th { background: #f9f9f9; font-size: 0.85rem; text-transform: uppercase; }
        .data-table tr:last-child td { border-bottom: none; }

        /* --- Pros & Cons Comparison --- */
        .comparison-grid {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 1rem;
        }
        .pros-box li::before { content: "✓"; color: var(--color-safe); font-weight: bold; margin-right: 8px; }
        .cons-box li::before { content: "✕"; color: var(--color-urgent); font-weight: bold; margin-right: 8px; }
        .pros-box, .cons-box { padding-left: 0.5rem; }
        .pros-box li, .cons-box li { margin-bottom: 0.5rem; font-size: 0.9rem; }

        /* --- Footer --- */
        footer {
            margin-top: 4rem;
            text-align: center;
            font-size: 0.8rem;
            color: #90a4ae;
            border-top: 1px solid #eceff1;
            padding-top: 2rem;
        }
        
        /* SVG Icon styling */
        svg { width: 24px; height: 24px; display: inline-block; vertical-align: middle; }
        .icon-lg svg { width: 48px; height: 48px; }

    </style>
</head>
<body>

    <header class="header">
        <div class="container header-content">
            <div>
                <span class="badge badge-blue">Clinical Reference</span>
                <h1 style="margin-top:0.5rem">PSA Testing: Asymptomatic Men</h1>
            </div>
            <div style="text-align:right">
                <p style="margin:0; font-weight:600; color:var(--color-text-primary)">Updated Dec 2025</p>
                <p style="margin:0; font-size:0.85rem">Based on PCRMP & NICE NG12</p>
            </div>
        </div>
    </header>

    <main class="container">

        <!-- HERO SECTION: CLINICAL DECISION MAKING -->
        <section class="triage-grid">
            
            <!-- Pathway A: Symptomatic -->
            <div class="triage-card triage-urgent" onclick="highlightSection('symptomatic-flow')">
                <div class="icon-lg" style="color:var(--color-urgent)">
                    <!-- Alert Icon -->
                    <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M10.29 3.86L1.82 18a2 2 0 0 0 1.71 3h16.94a2 2 0 0 0 1.71-3L13.71 3.86a2 2 0 0 0-3.42 0z"></path><line x1="12" y1="9" x2="12" y2="13"></line><line x1="12" y1="17" x2="12.01" y2="17"></line></svg>
                </div>
                <h2>Is Patient Symptomatic?</h2>
                <p>LUTS, Erectile Dysfunction, Visible Haematuria.</p>
                <div style="margin-top:1rem; padding-top:1rem; border-top:1px dashed #ccc;">
                    <strong style="color:var(--color-urgent)">Action Required:</strong>
                    <ul style="margin-top:0.5rem; list-style:disc; padding-left:1.2rem;">
                        <li>Clinical Assessment + DRE (if not contraindicated)</li>
                        <li>Refer via <strong>NICE NG12</strong> if PSA raised (Age-related thresholds)</li>
                        <li><strong>Do not</strong> use screening protocols.</li>
                    </ul>
                </div>
            </div>

            <!-- Pathway B: Asymptomatic -->
            <div class="triage-card triage-routine" onclick="highlightSection('asymptomatic-flow')">
                <div class="icon-lg" style="color:var(--color-safe)">
                    <!-- User Check Icon -->
                    <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M16 21v-2a4 4 0 0 0-4-4H5a4 4 0 0 0-4 4v2"></path><circle cx="8.5" cy="7" r="4"></circle><polyline points="17 11 19 13 23 9"></polyline></svg>
                </div>
                <h2>Is Patient Asymptomatic?</h2>
                <p>Requesting test "While I'm here" or via Campaign.</p>
                <div style="margin-top:1rem; padding-top:1rem; border-top:1px dashed #ccc;">
                    <strong style="color:var(--color-safe)">Action Required:</strong>
                    <ul style="margin-top:0.5rem; list-style:disc; padding-left:1.2rem;">
                        <li>Shared Decision Making (PCRMP).</li>
                        <li>Explain Overdiagnosis risk.</li>
                        <li>No National Screening Programme exists.</li>
                    </ul>
                </div>
            </div>

        </section>

        <!-- QUICK REFERENCE: NICE THRESHOLDS -->
        <section class="threshold-bar">
            <div>
                <h3 style="color:white; margin:0;">NICE NG12 Referral Thresholds</h3>
                <span style="font-size:0.8rem; opacity:0.8;">Use these values for both symptomatic & asymptomatic raised results</span>
            </div>
            <table class="threshold-table">
                <tr>
                    <td>40-49y</td>
                    <td>> 2.5 mcg/l</td>
                </tr>
                <tr>
                    <td>50-59y</td>
                    <td>> 3.5 mcg/l</td>
                </tr>
                <tr>
                    <td>60-69y</td>
                    <td>> 4.5 mcg/l</td>
                </tr>
                <tr>
                    <td>70-79y</td>
                    <td>> 6.5 mcg/l</td>
                </tr>
            </table>
        </section>

        <!-- RISK FACTORS DASHBOARD -->
        <h2>Risk Stratification Factors</h2>
        <section class="risk-section">
            
            <!-- Ethnicity -->
            <div class="card highlight">
                <h3><span class="badge badge-blue">Ethnicity</span></h3>
                <div class="risk-stat">1 in 4</div>
                <p><strong>Black men</strong> have a lifetime risk of 1 in 4, compared to 1 in 8 for White men.</p>
                <p style="font-size:0.85rem">PCRMP allows clinical discretion to test men under 50y if at higher risk. NSC draft guidance (Nov 2025) considers targeted screening for gene variants only (controversial).</p>
            </div>

            <!-- Family History -->
            <div class="card highlight">
                <h3><span class="badge badge-blue">Family History</span></h3>
                <table class="data-table">
                    <tr>
                        <td>No FH</td>
                        <td>8%</td>
                    </tr>
                    <tr>
                        <td>Father &lt;60y</td>
                        <td>20%</td>
                    </tr>
                    <tr>
                        <td>Brother &lt;60y</td>
                        <td>25%</td>
                    </tr>
                    <tr>
                        <td>>2 Relatives</td>
                        <td>30%+</td>
                    </tr>
                </table>
                <p style="margin-top:0.5rem; font-size:0.85rem">Earlier onset (&le;50y) common with genetic mutations.</p>
            </div>

            <!-- BRCA -->
            <div class="card highlight">
                <h3><span class="badge badge-blue">BRCA Mutations</span></h3>
                <div class="risk-stat">High Risk</div>
                <p>Men with <strong>BRCA2</strong> have increased risk of aggressive prostate cancer (Abs risk 27% by 75y).</p>
                <p style="font-size:0.85rem">EAU recommends PSA screening from age 40y. IMPACT study suggests BRCA1 carriers have 3x risk of aggressive disease.</p>
            </div>

        </section>

        <!-- INTERACTIVE TABS: DETAILS & EVIDENCE -->
        <div class="tabs">
            <button class="tab-btn active" onclick="openTab(event, 'consultation')">Consultation Flow</button>
            <button class="tab-btn" onclick="openTab(event, 'pros-cons')">Pros & Cons</button>
            <button class="tab-btn" onclick="openTab(event, 'mri-dre')">MRI & DRE</button>
            <button class="tab-btn" onclick="openTab(event, 'evidence')">Key Evidence</button>
        </div>

        <!-- Tab: Consultation -->
        <div id="consultation" class="tab-content active card">
            <h3>The PCRMP Process</h3>
            <p>When an asymptomatic man asks for a PSA test:</p>
            <div style="display:flex; gap:1rem; flex-wrap:wrap; margin-top:1rem;">
                <div style="flex:1; min-width:250px; background:#f8f9fa; padding:1rem; border-radius:8px;">
                    <strong style="display:block; margin-bottom:0.5rem; color:var(--color-info)">1. Check Eligibility</strong>
                    <p>Age 50+ (or under 50 if higher risk/clinical discretion).</p>
                </div>
                <div style="flex:1; min-width:250px; background:#f8f9fa; padding:1rem; border-radius:8px;">
                    <strong style="display:block; margin-bottom:0.5rem; color:var(--color-info)">2. Shared Decision Making</strong>
                    <p>Discuss benefits, harms, and limitations of the test. Ensure they understand overdiagnosis.</p>
                </div>
                <div style="flex:1; min-width:250px; background:#f8f9fa; padding:1rem; border-radius:8px;">
                    <strong style="display:block; margin-bottom:0.5rem; color:var(--color-info)">3. Result Management</strong>
                    <p>If raised: Refer via 2-week wait (Urgent) pathway based on local/NICE thresholds.</p>
                </div>
            </div>
            <div style="margin-top:1.5rem; background:#fff3e0; border-left:4px solid var(--color-warning); padding:1rem;">
                <strong>Important:</strong> Do not proactively raise the issue of PSA testing with asymptomatic men (PCRMP guidance). Only act upon request.
            </div>
        </div>

        <!-- Tab: Pros & Cons -->
        <div id="pros-cons" class="tab-content card">
            <div class="comparison-grid">
                <div style="background:#e0f2f1; padding:1.5rem; border-radius:8px;">
                    <h4 style="color:var(--color-safe)">Possible Advantages</h4>
                    <ul class="pros-box">
                        <li>Picks up cancer before symptoms start.</li>
                        <li>May detect fast-growing cancer early when treatment is effective.</li>
                        <li>Reassurance if result is normal (though not 100% sensitive).</li>
                    </ul>
                </div>
                <div style="background:#ffebee; padding:1.5rem; border-radius:8px;">
                    <h4 style="color:var(--color-urgent)">Possible Disadvantages</h4>
                    <ul class="cons-box">
                        <li>False positives: Raised PSA without cancer.</li>
                        <li>Overdiagnosis: Finding slow cancers that never cause harm.</li>
                        <li>Biopsy risks: Bleeding, infection, sepsis.</li>
                        <li>Treatment side effects: Urinary, bowel, erectile dysfunction.</li>
                    </ul>
                </div>
            </div>
            <div style="margin-top:1rem; padding:1rem; background:#f0f4f8; border-radius:8px;">
                <strong>By the numbers (BMJ Rapid Rec):</strong> ~1 in 7 asymptomatic men will have elevated PSA. 66% of men biopsied due to raised PSA do <strong>not</strong> have cancer.
            </div>
        </div>

        <!-- Tab: MRI & DRE -->
        <div id="mri-dre" class="tab-content card">
            <h3>Digital Rectal Examination (DRE)</h3>
            <div style="display:grid; grid-template-columns: 2fr 1fr; gap:1rem; align-items:start;">
                <div>
                    <p><strong>Current Status:</strong> NICE NG12 still recommends considering DRE for symptomatic men. However, BAUS/PCUK joint statement (June 2025) advises that if PSA is raised, refer for MRI; physical exam is not required prior to referral.</p>
                    <p><strong>Utility:</strong> DRE only palpates posterior wall; most cancer is anterior. A normal DRE <strong>does not</strong> exclude cancer. DRE is poor as a standalone screening tool (Ann Fam Med 2018).</p>
                </div>
                <div class="badge badge-red" style="text-align:center; padding:1rem;">
                    Do not use DRE to rule out cancer.
                </div>
            </div>

            <h3 style="margin-top:1.5rem;">Multiparametric MRI (mpMRI)</h3>
            <p>NICE recommends mpMRI as a first-step investigation before biopsy for men with raised PSA eligible for radical treatment.</p>
            <div class="comparison-grid" style="margin-top:1rem;">
                <div>
                    <strong style="display:block; margin-bottom:0.5rem; color:var(--color-safe)">Benefits</strong>
                    <ul class="pros-box">
                        <li>Reduces unnecessary biopsies by >25%.</li>
                        <li>Allows targeted biopsies of suspicious areas.</li>
                        <li>Improves detection of clinically significant cancer.</li>
                    </ul>
                </div>
                <div>
                    <strong style="display:block; margin-bottom:0.5rem; color:var(--color-text-secondary)">Impact on Screening</strong>
                    <p>Changes the risk-benefit balance of PSA testing by reducing the harm of biopsies. Future screening trials (e.g., TRANSFORM, GOTEBORG-2) focus on PSA + MRI.</p>
                </div>
            </div>
        </div>

        <!-- Tab: Evidence -->
        <div id="evidence" class="tab-content card">
            <h3>Summary of Key Trials</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Trial</th>
                        <th>Outcome (Long Term)</th>
                        <th>Key Takeaway</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>CAP (UK)</strong></td>
                        <td>No significant diff in mortality at 10y. Non-sig reduction at 15y.</td>
                        <td>Single PSA test not effective population screening.</td>
                    </tr>
                    <tr>
                        <td><strong>ERSPC (Europe)</strong></td>
                        <td>13% reduction in prostate cancer mortality after 23y.</td>
                        <td>Small benefit. 456 men need to screen to prevent 1 death. Increases overdiagnosis.</td>
                    </tr>
                    <tr>
                        <td><strong>PLCO (US)</strong></td>
                        <td>No difference in mortality.</td>
                        <td>Annual screening vs usual care showed no benefit.</td>
                    </tr>
                </tbody>
            </table>
            <div style="margin-top:1rem; font-size:0.9rem; color:var(--color-text-secondary);">
                *Note: None of these trials included modern mpMRI pathways, which may reduce harm profiles.
            </div>
        </div>

        <!-- RESOURCES -->
        <div style="margin-top:2rem;">
            <h3>Useful Resources</h3>
            <div style="display:flex; gap:1rem; flex-wrap:wrap;">
                <a href="#" class="badge badge-blue" style="text-decoration:none; padding:8px 12px;">PCRMP (Gov.uk)</a>
                <a href="#" class="badge badge-blue" style="text-decoration:none; padding:8px 12px;">MAGICapp Decision Aid</a>
                <a href="#" class="badge badge-blue" style="text-decoration:none; padding:8px 12px;">Prostate Cancer UK Risk Checker</a>
                <a href="#" class="badge badge-blue" style="text-decoration:none; padding:8px 12px;">NICE NG12 Guidelines</a>
            </div>
        </div>

    </main>

    <footer>
        <p><strong>Disclaimer:</strong> This tool is a summary of clinical guidance (BJGP 2025, NICE, PCRMP) and should be used alongside local protocols and clinical judgement.</p>
    </footer>

    <script>
        // Tab switching logic
        function openTab(evt, tabName) {
            // Get all elements with class="tab-content" and hide them
            var tabContent = document.getElementsByClassName("tab-content");
            for (var i = 0; i < tabContent.length; i++) {
                tabContent[i].style.display = "none";
                tabContent[i].classList.remove("active");
            }

            // Get all elements with class="tab-btn" and remove the class "active"
            var tabLinks = document.getElementsByClassName("tab-btn");
            for (var i = 0; i < tabLinks.length; i++) {
                tabLinks[i].className = tabLinks[i].className.replace(" active", "");
            }

            // Show the current tab, and add an "active" class to the button that opened the tab
            document.getElementById(tabName).style.display = "block";
            // Small timeout to allow display:block to render before adding opacity class for animation
            setTimeout(() => {
                document.getElementById(tabName).classList.add("active");
            }, 10);
            evt.currentTarget.className += " active";
        }

        // Visual feedback for Triage Cards
        function highlightSection(type) {
            // This is a placeholder for any specific interaction logic
            // Currently, the CSS hover states provide sufficient feedback
            // In a more complex app, this might auto-scroll to the relevant tab or show a modal.
            console.log("Focusing on: " + type);
        }
    </script>
</body>
</html>